|
Antibiotic substanceb
|
blaCTX-M, n = 80a
|
blaCTX-M-positive ESBL-producers, n = 58a
|
blaCTX-M-positive non ESBL producers, n = 22a
|
|---|
|
S
|
I
|
R
|
S
|
I
|
R
|
S
|
I
|
R
|
|---|
|
n
|
%
|
n
|
%
|
n
|
%
|
n
|
%
|
n
|
%
|
n
|
%
|
n
|
%
|
n
|
%
|
n
|
%
|
|---|
|
AM
|
0
|
–
|
0
|
–
|
80
|
100
|
0
|
–
|
0
|
–
|
58
|
100
|
0
|
–
|
0
|
–
|
22
|
100
|
|
AMC
|
48
|
60
|
9
|
11.3
|
23
|
28.8
|
40
|
69
|
9
|
15.5
|
9
|
15.5
|
8
|
36.4
|
0
|
–
|
14
|
63.6
|
|
TZP
|
64
|
80
|
9
|
11.3
|
7
|
8.8
|
51
|
87.9
|
6
|
10.3
|
1
|
1.7
|
13
|
59.1
|
3
|
13.6
|
6
|
27.3
|
|
CAZ
|
35
|
43.8
|
1
|
1.3
|
44
|
55
|
27
|
46.6
|
1
|
1.7
|
30
|
51.7
|
8
|
36.4
|
0
|
–
|
14
|
63.6
|
|
CTX
|
11
|
13.8
|
0
|
–
|
69
|
86.3
|
0
|
–
|
0
|
–
|
58
|
100
|
11
|
50
|
0
|
–
|
11
|
50
|
|
FEPc
|
37
|
50
|
10
|
13.5
|
27
|
36.5
|
29
|
55.8
|
8
|
15.4
|
15
|
28.8
|
8
|
36.4
|
2
|
9.1
|
12
|
54.5
|
|
ETP
|
77
|
96.3
|
2
|
2.5
|
1
|
1.3
|
57
|
98.3
|
1
|
1.7
|
0
|
–
|
20
|
90.9
|
1
|
4.5
|
1
|
4.5
|
|
IPM
|
80
|
100
|
0
|
–
|
0
|
–
|
58
|
100
|
0
|
–
|
0
|
–
|
22
|
100
|
0
|
–
|
0
|
–
|
|
MEM
|
80
|
100
|
0
|
–
|
0
|
–
|
58
|
100
|
0
|
–
|
0
|
–
|
22
|
100
|
0
|
–
|
0
|
–
|
|
AN
|
78
|
97.5
|
1
|
1.3
|
1
|
1.3
|
58
|
100
|
0
|
–
|
0
|
–
|
20
|
90.9
|
1
|
4.5
|
1
|
4.5
|
|
GM
|
52
|
65
|
3
|
3.8
|
25
|
31.3
|
39
|
67.2
|
1
|
1.7
|
18
|
31
|
13
|
59.1
|
2
|
9.1
|
7
|
31.8
|
|
CIP
|
18
|
22.5
|
1
|
1.3
|
61
|
76.3
|
14
|
24.1
|
1
|
1.7
|
43
|
74.1
|
4
|
18.2
|
0
|
–
|
18
|
81.8
|
- AMC: Amoxicillin/Clavulanic acid; TZP: Piperacillin/Tazobactam; ESBL: extended spectrum beta lactamase; CTX: Cefotaxime; CAZ: Ceftazidime; FEP: Cefepime; AN: Amikacin; CIP: Ciprofloxacin; S: susceptible; I: intermediate; R: resistant
- aMay not add up to 100% due to rounding errors to 1 decimal place
- bInterpretation of resistance according to the clinical breakpoints of CLSI
- c6 missing values for cefepime
